Rayence Co

Rayence Co Net Change in Cash

The Net Change in Cash of Rayence Co (228850.KQ) as of Nov 7, 2026 is -7.50 B KRW. In the previous year, Net Change in Cash was 865.24 M KRW — a change of -966.28% (lower).

Net Change in Cash

-7.50 BKRW

YoY

-966.28%

Last updated:

Net Change in Cash of Rayence Co is 2025 -7.50 B KRW. Net Change in Cash of Rayence Co was 2024 865.24 M KRW. It decreases by -966.28% lower compared to the previous year.

The Rayence Co Net Change in Cash history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Change in Cash
Date
Net Change in Cash
Jan 1, 2018
5.24 B KRW
Jan 1, 2019
1.50 B KRW
Jan 1, 2020
14.98 B KRW
Jan 1, 2021
-2.25 B KRW
Jan 1, 2022
13.03 B KRW
Jan 1, 2023
923.25 M KRW
Jan 1, 2024
865.24 M KRW
Jan 1, 2025
-7.50 B KRW
The Rayence Co Net Change in Cash history
YEARNet Change in CashYoY
-7.50 BKRW-966.28%
865.24 MKRW-6.28%
923.25 MKRW-92.91%
13.03 BKRW-678.15%
-2.25 BKRW-115.05%
14.98 BKRW+901.74%
1.50 BKRW-71.46%
5.24 BKRW-55.01%
11.65 BKRW-275.10%
-6.65 BKRW-244.27%
4.61 BKRW-1,246.91%
-402.00 MKRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Rayence Co Stock analysis

What does Rayence Co do? Rayence Co., Ltd. generates revenue through the manufacturing and sale of x-ray detectors, including TFT and CMOS detectors under brand names such as 1012WCA, 17SCC/SGC, 1215CF, 1501CF, and 0712CF. The company also produces intra oral sensors branded as Ez1.0 and Ez1.5, along with mammography machines under the 1724CM and 2434CM series. These products are distributed to both domestic and international markets, serving healthcare providers and medical facilities that require diagnostic imaging equipment. The primary customers for Rayence's detectors and sensors are hospitals, clinics, and medical imaging centers seeking advanced x-ray technology. The firm's product portfolio targets the medical imaging segment, focusing on applications such as dental diagnostics with intra oral sensors and radiological imaging with mammography machines. Revenue streams are derived from direct sales of these branded products to healthcare institutions across multiple regions. Rayence's business model centers on selling specialized medical imaging equipment under its own brand names, with no mention of third-party partnerships or additional services. The company's revenue is directly tied to the purchase of its branded x-ray detectors, intra oral sensors, and mammography machines by healthcare providers who require high-quality diagnostic tools for patient care. Rayence Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Rayence Co stock

Net Change in Cash of Rayence Co is -7.50 B KRW in 2025.

Net Change in Cash of Rayence Co changed from 865.24 M KRW to -7.50 B KRW, representing a -966.28% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Net Change in Cash Rayence Co since 2006 – with annual values, charts, and detailed analysis.

Net change in cash is the total change in cash and equivalents during the period, combining operating, investing, and financing cash flows.

Net Change in Cash's KRW is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Net Change in Cash's Rayence Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Rayence Co

All Key Metrics — Rayence Co